<DOC>
	<DOCNO>NCT01210274</DOCNO>
	<brief_summary>Myelodysplastic syndrome ( MDS ) frequent disease elderly patient ( median age : 71 year ) . IPSS classification defines low risk ( Low Intermediate 1 ) , high risk ( Intermediate 2 High ) MDS . High-risk MDS ( MDS-HR ) high risk transformation acute leukemia multilineage dysplasia ( AML-DML ) . The success Azacitidine mainly achieve rigorous empirical clinical research , molecular mechanism molecule exert effect remain poorly characterize . The primary mode action Azacytidine DNA demethylation , integration mRNA favor traduction inhibition . The impact molecule various cell death program involve elimination leukemic cell : apoptosis autophagy currently poorly know . The research program clinical study propose focus two major aspect : - Main objective : Molecular mechanism action resistance Azacitidine : Role apoptosis versus autophagy . - Secondary Objective : Reversion Azacytidine resistance use different drug target apoptosis and/or autophagy . Our laboratory identify new molecule selectively induce different type cell death ( apoptosis autophagy ) .</brief_summary>
	<brief_title>Characterization Mechanisms Resistance Azacitidine</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age â‰¥ 18 year High Risk Intermediate 2 MDS ( IPSS ) AMLMD ( WHO classification ) Treatment minimum three six cycle Azacitidine Informed consent form sign Treatment others chemotherapies alone association</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>